DelveInsight’s “Night Vision Disturbance Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the Night Vision Disturbance (NVD), historical and forecasted epidemiology as well as the Night Vision Disturbance (NVD) market trends in the United States, EU4 and the UK (Germany, France, Italy, Spain) and the United Kingdom, and Japan.
Discover Key Insights into the Night Vision Disturbance Market with DelveInsight’s In-Depth Report @ Night Vision Disturbance Market Size
Key Takeaways from the Night Vision Disturbance Market Report
- In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of Night Vision Disturbance (NVD) in the 7MM were nearly 55 million in 2023.
- The highest total diagnosed prevalent cases of Night Vision Disturbance (NVD) were accounted by the US in 2023 (44%), which are expected to show a rise in the future.
- Among the European countries, Germany had the highest diagnosed prevalent cases of Night Vision Disturbance (NVD) with ~6 million cases, followed by France, which had diagnosed prevalent population of ~4 million in 2023. On the other hand, Spain had the lowest prevalent population (~3 million cases).
- Japan had nearly 9 million total diagnosed prevalent cases of Night Vision Disturbance (NVD) in 2023, accounting for approximately 16% in 7MM.
- The leading Night Vision Disturbances Companies such as Ocuphire Pharma, Viatris, and others.
- Promising Night Vision Disturbances Therapies such as Nyxol, and others
Stay ahead in the Night Vision Disturbance Therapeutics Market with DelveInsight’s Strategic Report @ Night Vision Disturbance Market Outlook
Night Vision Disturbances Epidemiology Segmentation in the 7MM
- Total Prevalence of Night Vision Disturbances
- Prevalent Cases of Night Vision Disturbances by severity
- Gender-specific Prevalence of Night Vision Disturbances
- Diagnosed Cases of Episodic and Chronic Night Vision Disturbances
Download the report to understand which factors are driving Night Vision Disturbance epidemiology trends @ Night Vision Disturbance Prevalence
Night Vision Disturbance Emerging Drugs Profile
- Phentolamine Ophthalmic Solution 0.75% (Nyxol): Ocuphire Pharma/Viatris
Nyxol is a novel ophthalmic treatment for multiple front-of-the-eye disorders, including NVD and presbyopia. It is a proprietary ophthalmic formulation of phentolamine mesylate, an alpha-1 and alpha-2 inhibitor that has been approved previously as an injectable for other indications, allowing a more efficient development pathway for approval. Nyxol has demonstrated a differentiated product profile by moderately reducing pupil size (which leads to improved night and day vision), significantly lowering intraocular pressure, and convenient once-daily dosing. In September 2023, RYZUMVI (phentolamine ophthalmic solution) became a FDA-approved medicine to treat pharmacologically-induced mydriasis – dilation of the pupil of the eye caused by eye drops. Approval was supported by positive results in the MIRA-2 and MIRA-3 clinical trials. Ocuphire has a partnership with Viatris, Inc. to develop and commercialize phentolamine ophthalmic solution 0.75%.
Night Vision Disturbance Market Outlook
Currently, there is no definitive cure for NVD. Ophthalmologists typically conduct an assessment of NVD by examining the patient’s eyes and testing their vision. Early symptoms are best managed through observation, as the patient’s neural processing and adaptation mechanisms come into play. NVD treatment aims to mitigate symptoms and risk factors through diet modifications, pharmacological interventions, and invasive procedures as needed. Off-label usage of miotics, such as pilocarpine, carbachol, and aceclidine, and adrenergic agonists, such as brimonidine tartrate to reduce night vision symptoms in ophthalmology is significant.
Get In-Depth Knowledge on Night Vision Disturbance Market Trends and Forecasts with DelveInsight @ Night Vision Disturbance Treatment Market
Night Vision Disturbances Market Drivers
- Aging Population
- Growing Awareness
- Technological Advancements
- Increased Research & Development
- Rising Prevalence of Retinal Diseases
- Emerging Therapies
Night Vision Disturbances Market Barriers
- High Treatment Costs
- Limited Awareness in Rural Areas
- Availability of Standardized Treatment
- Slow Adoption of New Therapies
- Complex Regulatory Approvals
Scope of the Night Vision Disturbances Market Report
- Study Period: 2020-2034
- Coverage: 7MM
- Night Vision Disturbances Companies: Phentolamine Ophthalmic Solution 0.75% (Nyxol), and others
- Night Vision Disturbances Therapies: Ocuphire Pharma/Viatris, and others
- Night Vision Disturbances Therapeutic Assessment: Night Vision Disturbances current marketed and Night Vision Disturbances emerging therapies
- Night Vision Disturbances Market Dynamics: Night Vision Disturbances market drivers and Night Vision Disturbances market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Night Vision Disturbances Unmet Needs, KOL’s views, Analyst’s views, Night Vision Disturbances Market Access and Reimbursement
Unlock Strategic Insights with DelveInsight’s Comprehensive Night Vision Disturbance Market Report @ Night Vision Disturbance Market Drivers and Barriers
Table of Content
1. Key Insights
2. Report Introduction
3. Night Vision Disturbance (NVD) Market Share Distribution
4. Methodology of NVD Epidemiology and Market
5. Executive Summary of Night Vision Disturbance (NVD)
6. Key Events
7. Disease Background and Overview
8. Epidemiology and Patient Population
9. Patient Journey
10. Emerging Drug
11. NVD: Market Analysis
12. Key Opinion Leaders’ Views
13. SWOT Analysis
14. Unmet Needs
15. Market Access and Reimbursement
16. Appendix
17. Report Methodology
18. DelveInsight Capabilities
19. Disclaimer
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage